Bruker was seeing an appealing situation in 2025 after a strange year in 2024. Its aggressive M&A spree, funded by rising net debt and a $600M mandatory convertible preferred issuance, heightens ...
Great. Can everyone hear me? Can everyone hear us? Okay. Fantastic. Welcome, everyone. It's great to have you. Welcome, Gerald Herman, CFO of Bruker. I'm Aisyah Noor, European medtech analyst with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback